Oral lichen planus: Progress in understanding its malignant potential and the implications for clinical management

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 96, Issue 1, 2003, Pages 32-37

  Epstein, Joel B ^a,b,c,d,e   Wan, Laura S ^a   Gorsky, Meir ^f   Zhang, Lewei ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOAVAILABILITY; BIOTRANSFORMATION; CONTROLLED STUDY; DISEASE COURSE; DYSPLASIA; FOLLOW UP; HISTOLOGY; HISTORY OF MEDICINE; HUMAN; INFLAMMATION; LICHEN PLANUS; MEDICAL ASSESSMENT; RISK FACTOR; CELL TRANSFORMATION; GENETICS; HETEROZYGOSITY LOSS; MOUTH TUMOR; PATHOLOGY; REVIEW; RISK; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

IMMUNOSUPPRESSIVE AGENT;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LICHEN PLANUS, ORAL; LOSS OF HETEROZYGOSITY; MOUTH NEOPLASMS; RISK;

EID: 0141611816     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(03)00161-6     Document Type: Article

References (79)

1. Eisen D. The therapy of oral lichen planus. Crit Rev Oral Biol Med. 4:1993;141-158.
2. Chainani-Wu N., Silverman S. Jr, Lozada-Nur F., Mayer P., Watson J.J. Oral lichen planus patient profile, disease progression and treatment responses. J Am Dent Assoc. 132:2001;901-909.
3. Lozada-Nur F., Miranda C. Oral lichen planus epidemiology, clinical characteristics, and associated diseases. Semin Cutan Med Surg. 16:1997;273-277.
4. Pindborg JJ, Reichart PA, Smith CJ, Sobin LH. WHO International Histological Classification of Tumors: Histological Typing of Cancer and Precancer of the Oral Mucosa. Berlin: Springer; 1997.
5. Miller C.S., Epstein J.B., Hall E.H., Sirois D. Changing oral care needs in the United States the continuing need for oral medicine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 91:2001;34-44.
6. Silverman S., Gorsky M., Lozada-Nur F. A prospective follow-up study of 570 patients with oral lichen planus persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol. 60:1985;30-34.
7. Gorsky M., Raviv M., Moskona D., Laufer M., Bodner L. Clinical characteristics and treatment of patients with oral lichen planus in Israel. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 82:1996;644-649.
8. van der Meij E.H., Reibel J., Slootweg P.J., van der Wal J.E., de Jong W.F., van der Waal I. Interobserver and intraobserver variability in the histology assessment of oral lichen planus. J Oral Pathol Med. 28:1999;274-277.
9. Krutchkoff D.J., Eisenberg E. Lichenoid dysplasia a distinct histopathologic entity. Oral Surg Oral Med Oral Pathol. 30:1985;308-315.
10. Eisenberg E. Oral lichen planus a benign lesion. J Oral Maxillofac Surg. 58:2000;1278-1285.
11. Krutchkoff D.J., Cutler L., Laskowski S. Oral lichen planus the evidence regarding potential malignant transformation. J Oral Pathol. 7:1978;1-7.
12. Urbizo-Velez J., Rodriguez Perez I., Albrecht M., Banoczy J. Comparative histopathological studies in oral lichen planus. Acta Morphol Hung. 38:1990;71-81.
13. De Jong W.F., Albrecht M., Banoczy J., van der Waal I. Epithelial dysplasia in oral lichen planus. Int J Oral Surg. 13:1984;221-225.
14. Silverman S. Jr. Oral lichen planus a potentially premalignant lesion. J Oral Maxillofac Surg. 58:2000;1286-1288.
15. Silverman S. Jr, Gorsky M., Lozada-Nur F., Giannotti K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 72:1991;665-670.
16. Barnard N.A., Scully C., Eveson J.W., Cunningham S., Porter S.R. Oral cancer development in patients with oral lichen planus. J Oral Pathol Med. 22:1993;421-424.
17. Silverman S. Jr, Bahl S. Oral lichen planus update clinical characteristics, treatment responses, and malignant transformation. Am J Dent. 10:1997;259-263.
18. van der Meij E.H., Schepman K.P., Smeele L.E., van der Wal J.E., Bezemer P.D., van der Waal I. A review of the recent literature regarding malignant transformation of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 88:1999;307-310.
19. Hietanen J., Paasonen M.R., Kuhlefelt M., Malmstrom M. A retrospective study of oral lichen planus patients with concurrent or subsequent development of malignancy. Oral Oncol. 35:1999;278-282.
20. Zhang L., Poh C.F., Lam W.L., Epstein J.B., Cheng X., Zhang X., et al. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia molecular evidence of incomplete resection. Oral Oncol. 37:2001;505-512.
21. Zhang L., Cheung K.J. Jr, Lam W.L., Cheng X., Poh C., Priddy R., et al. Increased genetic damage in oral leukoplakia from high risk sites potential impact on staging and clinical management. Cancer. 91:2001;2148-2155.
22. Rosin M.P., Cheng X., Poh C., Lam W.L., Huang Y., Lovas J., et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 6:2000;357-362.
23. Mao L., Lee J.S., Fan Y.H., Ro J.Y., Batsakis J.G., Lippman S., et al. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 2:1996;682-685.
24. Partridge M., Pateromichelakis S., Phillips E., Emilion G.G., A'Hern R.P., Langdon J.D. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 60:2000;3893-3898.
25. Lee J.J., Hong W.K., Hittelman W.N., Mao L., Lotan R., Shin D.M., et al. Predicting cancer development in oral leukoplakia ten years of translational research. Clin Cancer Res. 6:2000;1702-1710.
26. Zhang L., Epstein J., Band P., Berean K., Hay J., Cheng X., et al. Local tumor recurrence or emergence of a new primary lesion? A molecular analysis. J Oral Pathol Med. 28:1999;381-384.
27. Califano J., Westra W.H., Meininger G., Corio R., Koch W.M., Sidransky D. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res. 6:2000;347-352.
28. Cairns P., Sidransky D. Molecular methods for the diagnosis of cancer. Biochim Biophys Acta. 1423:1999;C11-18.
29. Ahrendt S.A., Sidransky D. The potential of molecular screening. Surg Oncol Clin N Am. 8:1999;641-656.
30. Mao L. Can molecular assessment improve classification of head and neck premalignancy? Clin Cancer Res. 6:2000;321-322.
31. Brennan J.A., Mao L.L., Hruban R.H., Boyle J.O., Eby Y.J., Koch W.M., et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med. 332:1995;429-435.
32. Guo Z., Yamaguchi K., Sanchez-Cespedes M., Westra W.H., Koch W.M., Sidransky D. Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res. 7:2001;1963-1968.
33. Schoelch M.L., Sekandari N., Regezi J.A., Silverman S. Jr. Laser management of oral leukoplakias a follow-up study of 70 patients. Laryngoscope. 109:1999;949-953.
34. Beenken S.W., Sellers M.T., Huang P., Peters G., Krontiras H., Dixon P., et al. Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia modulation by 13-cis retinoic acid. Head Neck. 21:1999;566-573.
35. Sudbo J., Kildal W., Risberg B., Kopang H.S., Danielsen H.E., Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med. 44:2001;1270-1278.
36. Scully C., Field J.K., Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 3 clinico-pathological applications. Oral Oncol. 36:2000;404-413.
37. Scully C., Field J.K., Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 2 chromosomal aberrations. Oral Oncol. 36:2000;311-327.
38. Scully C., Field J.K., Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN) 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 36:2000;256-263.
39. Zhang L., Michelsen C., Cheng X., Zeng T., Priddy R., Rosin M.P. Molecular analysis of oral lichen planus. A premalignant lesion? Am J Pathol. 151:1997;323-327.
40. Zhang L., Cheng X., Li Y., Poh C., Zeng T., Priddy R., et al. High frequency of allelic loss in dysplastic lichenoid lesions. Lab Invest. 80:2000;233-237.
41. Kim J., Yook J.I., Lee E.H., Ryu M.H., Yoon J.H., Hong J.C., et al. Evaluation of premalignant potential in oral lichen planus using interphase cytogenetics. J Oral Pathol Med. 30:2001;65-72.
42. Mignogna M.D., Lo Muzio L., Lo Russo L., Fedele S., Ruoppo E., Bucci E. Clinical guidelines in early detection of oral squamous cell carcinoma arising in oral lichen planus a 5-year experience. Oral Oncol. 37:2001;262-267.
43. Onofre M.A., Sposto M.R., Navarro C.M. Reliability of toluidine blue application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 91:2001;535-540.
44. Epstein J.B., Oakley C., Millner A., Emerton S., van der Meij E., Le N. The utility of toluidine blue application as a diagnostic aid in patients previously treated for upper oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 83:1997;537-547.
45. Epstein J.B., Scully C., Spinelli J. Toluidine blue and Lugol's iodine application in the assessment of oral malignant disease and lesions at risk of malignancy. J Oral Pathol Med. 21:1992;160-163.
46. Rosenberg D., Cretin S. Use of meta-analysis to evaluate tolonium chloride in oral cancer screening. Oral Surg Oral Med Oral Pathol. 67:1989;621-627.
47. Warnakulasuriya K.A., Johnson N.W. Sensitivity and specificity of OraScan toluidine blue mouthrinse in the detection of oral cancer and precancer. J Oral Pathol Med. 25:1996;97-103.
48. Martin I.C., Kerawala C.J., Reed M. The application of toluidine blue as a diagnostic adjunct in the detection of epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 85:1998;444-446.
49. Pizer M.E., Dubois D.D. An assessment of toluidine blue for the diagnosis of lip lesions. Va Med. 106:1979;860-862.
50. Mashberg A., Samit A. Early detection, diagnosis, and management of oral and oropharyngeal cancer. CA Cancer J Clin. 45:1995;328-351.
51. Portugal L.G., Wilson K.M., Biddinger P.W., Gluckman J.L. The role of toluidine blue in assessing margin status after resection of squamous cell carcinomas of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 122:1996;517-519.
52. Kerawala C.J., Beale V., Reed M., Martin I.C. The role of vital tissue staining in the marginal control of oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 29:2000;32-35.
53. Sciubba J.J. Improving detection of precancerous and cancerous oral lesions. Computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc. 130:1999;1445-1457.
54. Rosin M.P., Epstein J.B., Berean K., Durham S., Hay J., Cheng X., et al. The use of exfoliative cell samples to map clonal genetic alterations in the oral epithelium of high-risk patients. Cancer Res. 57:(23):1997;5258-5260.
55. Lozada-Nur F., Miranda C. Oral lichen planus topical and systemic therapy. Semin Cutan Med Surg. 16:1997;295-300.
56. Demitsu T., Sato T., Inoue T., Okada O., Kubota T. Corticosteroid- resistant erosive oral lichen planus successfully treated with topical cyclosporine therapy. Int J Dermatol. 39:2000;79-80.
57. Epstein J.B., Gorsky M., Epstein M.S., Nantel S. Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions a series of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 91:2001;56-61.
58. Epstein J.B., Truelove E.L. Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions an open label clinical trial. Oral Surg Oral Med Oral Pathol. 82:1996;532-536.
59. Nousari H.C., Goyal S., Anhalt G.J. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Dermatol. 135:1999;1420-1421.
60. Popovsky J.L., Camisa C. New and emerging therapies for diseases of the oral cavity. Dermatol Clin. 18:2000;113-125.
61. Zouboulis C.C. Retinoids - which dermatological indications will benefit in the future? Skin Pharmacol Appl Skin Physiol. 14:2001;303-315.
62. Buajeeb W., Kraivaphan P., Pobrurksa C. Efficacy of topical retinoic acid compared with topical fluocinolone acetonide in the treatment of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 83:1997;21-25.
63. Epstein J.B., Gorsky M. Topical application of vitamin A to oral leukoplakia a clinical case series. Cancer. 86:1999;921-927.
64. Epstein J.B., Gorsky M., Wong F.L., Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer. 83:1998;629-634.
65. Epstein J.B., Scully C. Assessing the patient at risk for oral squamous cell carcinoma. Spec Care Dentist. 17:1997;120-128.
66. Femiano F., Gombos F., Scully C. Oral proliferative verrucous leukoplakia (PVL); open trial of surgery compared with combined therapy using surgery and methisoprinol in papillomavirus-related PVL. Int J Oral Maxillofac Surg. 30:2001;318-322.
67. Saito T., Sugiura C., Hirai A., Notani K., Totsuka Y., Shindoh M., et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia with respect to treatment modality. Int J Oral Maxillofac Surg. 30:2001;49-53.
68. 2 laser therapy of oral mucosal lesions. J Clin Laser Med Surg. 16:1998;299-304.
69. Leunig A., Betz C.S., Baumgartner R., Grevers G., Issing W.J. Initial experience in the treatment of oral leukoplakia with high-dose vitamin A and follow-up 5-aminolevulinic acid induced protoporphyrin IX fluorescence. Eur Arch Otorhinolaryngol. 257:2000;327-331.
70. Hyde N., Hopper C. Oral cancer the importance of early referral. Practitioner. 243:1999;753. passim, 756-8, 760-1.
71. Gooris P.J., Roodenburg J.L., Vermey A., Nauta J.M. Carbon dioxide laser evaporation of leukoplakia of the lower lip a retrospective evaluation. Oral Oncol. 35:1999;490-495.
72. Tete S., Pappalardo S., Rubini C., Salini L., Falco A., Perfetti E.G. The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin. Minerva Stomatol. 48:1999;411-418.
73. Piattelli A., Fioroni M., Santinelli A., Rubini C. bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia a pilot study. Oral Oncol. 35:1999;314-320.
74. Garewal H.S., Katz R.V., Meyskens F., Pitcock J., Morse D., Friedman S., et al. Beta-carotene produces sustained remissions in patients with oral leukoplakia results of a multicenter prospective trial. Arch Otolaryngol Head Neck Surg. 125:1999;1305-1310.
75. Kubler A., Haase T., Rheinwald M., Barth T., Muhling J. Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid. Int J Oral Maxillofac Surg. 27:1998;466-469.
76. Khafif A., Schantz S.P., al-Rawi M., Edelstein D., Sacks P.G. Green tea regulates cell cycle progression in oral leukoplakia. Head Neck. 20:1998;528-534.
77. Lippman S.M., Lee J.J., Sabichi A.L. Cancer chemoprevention progress and promise. J Natl Cancer Inst. 90:1998;1514-1528.
78. Gorsky M, Epstein JB. The effect of retinoids on oral premalignant lesions. Focus on topical therapy. Cancer accepted 2002.
79. Garcia-Pola VJM, Garcia MJM, Gonzales GM, Tenentk AP. Precancerous lesions (oral leukoplakia and lichen planus). Atençion Primera 1998;20:41-4.